Henry Wheeler

Head of Investor Relations

Equibles does not estimate personal net worth.

Get an email with a short summary when Innate Pharma SA publishes a filing, an earnings call transcript or a press release.

Get IPHA alerts

About Henry Wheeler

Henry Wheeler is recorded as Head of Investor Relations at Innate Pharma SA (IPHA). Henry Wheeler has spoken on 11 earnings calls across 1 company, most recently for Innate Pharma SA on March 31, 2025. Innate Pharma SA is classified in the Biotechnology industry within the Healthcare sector.

Henry Wheeler on recent calls

“This morning, Innate issued a press release for our Q1 2025 Business Update and Financial Results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones.”

Head of Investor Relations, Innate Pharma SA Q1 FY2025 Earnings Call · March 31, 2025

“This morning, Innate issued a press release for our Q3 2024 business updates and financial results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones.”

Head of Investor Relations, Innate Pharma SA Q3 FY2024 Earnings Call · September 30, 2024

“This morning, Innate issued a press release for our H1 business update and financial results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones.”

Head of Investor Relations, Innate Pharma SA Q2 FY2024 Earnings Call · June 25, 2024

“This morning Innate issued a press release for our Q1 2024 business update and financial results. We look forward to highlighting the progress made during the year-to-date, during the quarter-to-date, as well as addressing future goals and milestones.”

Head of Investor Relations, Innate Pharma SA Q1 FY2024 Earnings Call · March 31, 2024

“This morning, Innate issued a press release for our full year 2023 financial results and business update. We look forward to highlighting the progress made during the year to date as well as addressing future goals and milestones.”

Head of Investor Relations, Innate Pharma SA Q4 FY2023 Earnings Call · December 31, 2023